Assessing the Antiangiogenic Effects of Chalcones and Their Derivatives
Date
19 Jan 202Author
Hepokur ,CeylanSerdar, Burmaoglu
Arzu,Gobek
Derya,Aktas Anil
Mehmet ,Abdullah Alagoz
Adem,Guner
Cem, Guler
N. Ulku,Karabay Yavasoglu
Oztekin,Algul
Metadata
Show full item recordAbstract
Pathological angiogenesis plays a critical role in tumorigenesis and tumor pro gression, and anti-angiogenesis therapies have evinced promising antitumor
effects in solid tumors. Chalcone skeleton has been regarded as a potential
antitumor agent that also targets angiogenesis. In this study, we designed
twenty-one non-fluoro-substituted chalcones (13–18, 24–27) and saturated
chalcone derivatives (19–23, 28–33) as anti-angiogenic compounds. During
the initial stage, these compounds were assessed for their anti-cancer activities
against MCF-7 cancer cell lines according to the MTT assay. The compounds
revealed satisfactory anti-proliferative capability. An ex vivo fertilized hens’
egg-chorioallantoic membrane (HET-CAM) angiogenic study was conducted
for the compounds to gauge their mortality and toxicity, which, in turn,
revealed a potent anti-angiogenic effect. Eight compounds (16, 17, 21, 24, 26,
27, 29, and 31) significantly reduced densities of capillaries on CAM, whereas
compounds 27 and 29 were the most effective anti-angiogenic agents, when
compared with Suramin. Moreover, RT-qPCR analysis demonstrated that the
anti-angiogenic activity was associated with the fold changes of VEGFR2.
Molecular docking studies were conducted for compounds to investigate their
mode of interaction within the binding site of VEGFR-2 kinases. This work pro vided a basis for further design, structural modification, and development of
chalcone derivatives as new anti-angiogenic agents.